Tirzepatide price without insurance: real 2025 numbers

Last updated 2026-07-30

What does tirzepatide actually cost without insurance?

The honest answer depends entirely on which product you mean, because "tirzepatide" now covers three very different price categories. Eli Lilly's FDA-approved branded drugs (Zepbound for weight loss, Mounjaro for type 2 diabetes) have list prices north of $1,000 a month. Compounded tirzepatide, made by licensed compounding pharmacies and dispensed through telehealth platforms, typically costs $150 to $500 a month. There's no generic tirzepatide in the US yet; the compound is still under patent, and Lilly's exclusivity doesn't expire until the early 2030s in most projections. As of 2025, Zepbound's list price for a one-month supply is $1,059.87, according to Eli Lilly's own pricing statements ^[1]. Mounjaro lists at $1,069.03 a month. These are list prices, meaning what a pharmacy would charge before any manufacturer discount, insurance negotiation, or savings card is applied. Almost nobody actually pays list price for long, either because insurance negotiates it down, or because Lilly's own savings programs intervene. What you'll actually pay without insurance splits into three real scenarios: full list price at a retail pharmacy (rare, and honestly a bad deal), Lilly's direct-to-consumer self-pay program through LillyDirect (cheaper), or compounded tirzepatide through a telehealth clinic (cheapest, with real caveats). We'll walk through all three below with actual numbers.

How much is Zepbound without insurance, exactly?

Zepbound's list price is $1,059.87 per month regardless of dose, but almost no cash-paying patient pays that number. Lilly runs a direct self-pay program through LillyDirect that drops the price meaningfully for people without insurance coverage for the drug. As of Lilly's published 2025 pricing, self-pay patients using LillyDirect can get Zepbound vials at $349 a month for the 2.5 mg and 5 mg starter doses, and $499 a month for the 7.5 mg through 15 mg doses, when paying cash and using the single-dose vial format rather than the auto-injector pen. This is a genuinely large discount off list, roughly 53% to 67% off, and it's Lilly's direct answer to compounded competition. The catch: the vial program requires self-injection with a syringe (not the pre-filled pen), and it's only available to patients without insurance coverage for Zepbound specifically (having other health insurance doesn't disqualify you, but if your plan covers Zepbound, you're supposed to use that instead). If you want the pen device, list-price territory returns unless a manufacturer coupon applies. Patients with commercial insurance that excludes GLP-1 weight-loss drugs (extremely common; most large employer plans don't cover them) have historically been the main users of Lilly's older $550 savings card program, which has periodically closed enrollment as demand outstripped the discount pool.

How much is Mounjaro without insurance?

Mounjaro, the type 2 diabetes version of the same drug, lists at $1,069.03 a month. If you're prescribed Mounjaro off-label for weight loss (common, since it's approved at different doses under the Zepbound brand for that use), you generally can't access Zepbound's cash-pay vial pricing, because that program is specific to the Zepbound-branded product and indication. Mounjaro does have its own savings card for commercially insured patients, historically bringing costs as low as $25 a month for those whose insurance covers Mounjaro for diabetes but leaves a copay. That card explicitly excludes people on Medicare, Medicaid, or other federal insurance programs, and it doesn't help people with zero insurance at all. If you're uninsured and prescribed Mounjaro for diabetes, you're largely looking at list price or a patient assistance program application, which takes time and isn't guaranteed.

Why is compounded tirzepatide so much cheaper?

Compounded tirzepatide runs $150 to $500 a month at most telehealth clinics, roughly a third to a fifth of Zepbound's list price. The core reason is regulatory, more than business strategy: compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act aren't required to run the drug through FDA's approval pipeline, which is where a huge share of brand-name drug cost gets built in. During 2022 through 2024, tirzepatide appeared on FDA's drug shortage list, which under federal law temporarily allowed compounding pharmacies to make copies of an approved drug even when a commercial version existed ^[2]. FDA removed tirzepatide injection products from the shortage list in December 2024 ^[3], and by early 2025 was actively signaling it would move to stop most non-personalized compounding of the drug except under narrow 503A/503B exceptions. That regulatory shift has already forced some compounders to stop selling standard tirzepatide copies, or pivot toward legally distinct "personalized" formulations (adding B12, glycine, or other components) that some legal experts argue still sit in gray territory. The price gap is real and mechanically explainable: no brand marketing spend, no patent royalty, cheaper raw active pharmaceutical ingredient sourcing, and a leaner regulatory pathway. It is not evidence that compounded product matches an FDA-approved, batch-tested Lilly product on quality control. FDA has published warnings about adverse events tied to compounded tirzepatide, including dosing errors from providers and patients miscalculating doses drawn from multi-dose vials ^[4].

Is compounded tirzepatide legal and safe?

Compounded tirzepatide is legal when made by a licensed 503A pharmacy for an individual patient prescription, or by a 503B outsourcing facility, but its legal footing has narrowed significantly since the shortage ended. The FFDCA's compounding exceptions (503A and 503B) exist specifically for drugs that are in shortage, are personalized for a patient's documented clinical need, or aren't otherwise commercially available in the needed form ^[2]. Once FDA declared tirzepatide's shortage resolved in December 2024 ^[3], the shortage-based justification for mass compounding effectively disappeared, and litigation and enforcement activity followed. Safety is a separate question from legality. FDA has specifically flagged concerns about compounded semaglutide and tirzepatide products using salt forms (like tirzepatide sodium or tirzepatide acetate) not found in the FDA-approved drug, warning that these have not been shown safe or effective and that their sterility and purity aren't verified the way an approved drug's are ^[5]. If you're going the compounded route, the practical safety floor is: use a facility that's actually licensed as 503A or 503B (verifiable through your state board of pharmacy), get third-party certificate of analysis testing where the clinic provides it, and treat any "personalized" additive as a marketing choice rather than a clinical upgrade with its own evidence base.

What's the real monthly cost comparison across options?

Here's the actual spread as of 2025, in plain numbers. | Option | Typical monthly cost | Notes |

Does Medicare or Medicaid cover tirzepatide?

Medicare Part D has historically been barred from covering drugs for weight loss alone, under a longstanding statutory exclusion for "agents when used for anorexia, weight loss, or weight gain" in Medicare Part D law ^[7]. That's why Medicare could cover Mounjaro for type 2 diabetes but not Zepbound for obesity, until CMS proposed a policy change. In November 2024, CMS proposed reinterpreting anti-obesity medications as covered when treating obesity as a disease, which would have let Medicare and Medicaid cover Zepbound and similar drugs starting in 2026 ^[8]. That proposal was still pending as of early 2025 and its final status under the current administration is uncertain, so anyone budgeting around Medicare coverage should check CMS's current final rule rather than assume the 2024 proposal survived intact. Medicaid coverage varies enormously by state; some states cover GLP-1 drugs for obesity, most historically have not, and this is a genuinely moving target worth checking against your specific state Medicaid formulary before assuming either way.

Are there ways to lower the price legitimately?

A few levers actually move the needle, and a few commonly cited ones don't do much. What helps: Lilly's LillyDirect vial program if you have no insurance coverage for the drug (real 50%+ discount off list). Manufacturer savings cards if you have commercial insurance with a partial exclusion or high copay (these have had enrollment caps in past years, so check current status). Patient assistance programs for genuinely low-income, uninsured patients, run directly through Lilly, which have income eligibility cutoffs and require documentation. Comparing 503A/503B compounding pharmacies directly if you've decided that route is right for you, since prices vary by a factor of two or three between clinics. What doesn't help much: shopping different retail pharmacies for list-price Zepbound or Mounjaro (prices are close to uniform since it's the same manufacturer list price feeding most retail chains). International pharmacy importation (legally murky under FDA import rules and carries real quality-control unknowns). Buying larger supply quantities upfront from a compounder to get a "bulk discount" without verifying the pharmacy's licensing first.

What does the FDA evidence actually say tirzepatide does, and does the price reflect real trial results?

Whatever price tier you're paying, the drug's efficacy data is genuinely strong, which is part of why demand (and price) hasn't softened. The SURMOUNT-1 trial (NCT04184622), published in the New England Journal of Medicine, found that participants without diabetes lost an average of 20.9% of body weight on the highest tirzepatide dose (15 mg) over 72 weeks, compared to 3.1% on placebo ^[9]. For type 2 diabetes, the SURPASS-2 trial (NCT03987919) found tirzepatide reduced HbA1c by up to 2.30 percentage points at the highest dose, outperforming semaglutide 1 mg in head-to-head comparison . Those are real, FDA-reviewed numbers behind the approval, not marketing claims. It's a fair question whether $1,000-plus a month is a fair price for that effect size; that's a value judgment reasonable people land on differently, and it's worth reading a fuller tirzepatide reviews breakdown or the tirzepatide results timeline before deciding if the cost matches your goals. What the price does not reflect is any difference in efficacy between brand and legitimately compounded versions of the drug itself; the difference is in manufacturing oversight, batch testing, and FDA approval status.

What side effects and risks should factor into a cost decision?

Price matters, but so does the fact that tirzepatide carries a real side effect profile you're paying to manage regardless of which version you buy. The most common adverse effects across the SURMOUNT and SURPASS trials were gastrointestinal: nausea, diarrhea, constipation, and vomiting, typically worse during dose escalation and easing over time ^[9] . These aren't rare; in SURMOUNT-1, nausea occurred in roughly 25-30% of participants across dose groups. More serious risks include a signal for acute pancreatitis and gallbladder disease (cholelithiasis and cholecystitis), both flagged in FDA prescribing information for Zepbound and Mounjaro . Tirzepatide also carries a boxed warning, the FDA's most serious label warning, for risk of thyroid C-cell tumors based on rodent studies; the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) . That warning applies the same way whether you're getting brand-name or compounded tirzepatide, because it's a property of the drug's mechanism, not the manufacturing process. Anyone weighing cost should also weigh whether they're a good candidate at all given personal or family thyroid cancer history, gallbladder disease history, or pancreatitis history, separate from what they can afford. A cheaper compounded version doesn't reduce these risks; it just changes who's watching quality control on the way to your syringe.

So what's the actual smart move for a cash-paying patient?

If you have zero insurance coverage for GLP-1 weight-loss drugs and want the FDA-approved product with full manufacturing oversight, the LillyDirect Zepbound vial program at $349 to $499 a month is the best legitimate value in the branded space right now, a real 53-67% discount off list price. It requires comfort with self-injection via vial and syringe rather than the pen. If that's still out of budget, compounded tirzepatide from a licensed 503A or 503B pharmacy, verified through your state pharmacy board, and prescribed through a legitimate telehealth provider after real medical screening, is the realistic $150-500 a month alternative. The tradeoff is less standardized quality assurance and a narrowing legal runway following FDA's December 2024 shortage resolution ^[3]. What's not worth it: paying full list price ($1,000+) at a retail pharmacy without checking LillyDirect first, or buying from an unlicensed online seller with no prescriber screening at all, which is where most of the genuinely dangerous product ends up. Before committing either way, it's worth reading up on is tirzepatide worth it and the tirzepatide pros and cons breakdown, since the cost only makes sense in context of expected results and how long you'd realistically stay on it. Tirz Rx's own coverage points toward the provider-reviewed telehealth route, working with a licensed pharmacy partner rather than unverified online sellers, as the more defensible middle ground between full list price and buying from an anonymous website.

Frequently asked questions

How much does tirzepatide cost per month without insurance?

Brand-name Zepbound lists at $1,059.87 a month and Mounjaro at $1,069.03, per Eli Lilly's published pricing. Lilly's LillyDirect self-pay vial program brings Zepbound down to $349-$499 a month for uninsured patients. Compounded tirzepatide through telehealth clinics typically runs $150-$500 a month, though quality oversight varies by pharmacy.

Why is Zepbound so expensive?

Zepbound's price reflects FDA approval costs, patent-protected exclusivity, and manufacturing under strict pharmaceutical GMP standards. Eli Lilly holds patent protection into the early 2030s, meaning no generic competition exists yet. List price is $1,059.87/month, though most patients pay less through savings programs, insurance, or the LillyDirect self-pay vial option.

Is compounded tirzepatide the same as Zepbound or Mounjaro?

Compounded tirzepatide is generally prepared to the same drug specification, but it is not FDA-approved as a finished product, meaning it hasn't undergone the same batch testing, sterility verification, and manufacturing oversight as Zepbound or Mounjaro. Some compounders use different salt forms (tirzepatide sodium or acetate) that FDA has specifically flagged as unverified for safety and effectiveness.

Can I still get compounded tirzepatide legally in 2025?

It depends on the pharmacy's licensing and your prescription's basis. FDA ended tirzepatide's official shortage designation in December 2024, which removed the main legal justification for mass compounding. Licensed 503A pharmacies can still compound for individual patient needs, and 503B outsourcing facilities operate under separate rules, but the legal landscape is narrowing and shifting.

Does Medicare cover tirzepatide?

Medicare Part D has historically excluded coverage for weight-loss drugs by statute, though it can cover Mounjaro for type 2 diabetes. CMS proposed in November 2024 to reclassify anti-obesity drugs as covered treatment for obesity as a disease starting in 2026; the final status of that rule should be confirmed directly with CMS before budgeting around it.

What is the LillyDirect Zepbound vial program?

It's Eli Lilly's direct-to-consumer cash-pay option for patients without insurance coverage for Zepbound. It offers vials (self-injected via syringe, not the pre-filled pen) at $349/month for 2.5mg-5mg doses and $499/month for 7.5mg-15mg doses, roughly 53-67% off the $1,059.87 list price.

How much is Mounjaro's savings card worth?

Lilly's Mounjaro savings card has historically brought costs as low as $25/month for commercially insured patients whose plan covers Mounjaro but leaves a copay. It explicitly excludes Medicare, Medicaid, and other federal insurance program enrollees, and doesn't help patients with zero insurance coverage.

Why do compounding pharmacies charge so much less than Lilly?

Compounders skip the FDA new-drug approval pipeline, brand marketing costs, and patent royalties, and often source active ingredient more cheaply. Under FFDCA Sections 503A and 503B, licensed compounders can legally prepare drug copies during shortages or for personalized patient needs, which historically let them price tirzepatide copies at $150-500/month versus $1,000+ for brand name.

What are the real side effects of tirzepatide regardless of price?

The most common are gastrointestinal: nausea, diarrhea, vomiting, and constipation, occurring in roughly a quarter to a third of trial participants. More serious risks include pancreatitis and gallbladder disease. Tirzepatide carries an FDA boxed warning for thyroid C-cell tumor risk and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.

Is it cheaper to get tirzepatide through Mounjaro instead of Zepbound if I don't have diabetes?

Not necessarily cheaper for cash payers, since Mounjaro doesn't have an equivalent to Zepbound's discounted self-pay vial program. Off-label Mounjaro prescribing for weight loss also means you can't use Mounjaro's diabetes-specific savings card as intended, and insurance often denies off-label claims outright.

How much weight does tirzepatide actually help you lose, to justify the cost?

In the SURMOUNT-1 trial (NCT04184622), participants without diabetes lost an average of 20.9% of body weight on the 15mg dose over 72 weeks, versus 3.1% on placebo. Individual results vary substantially, and maintaining loss typically requires staying on the drug or a comparable long-term plan.

Are there patient assistance programs for tirzepatide?

Yes, Eli Lilly runs income-based patient assistance programs for both Zepbound and Mounjaro, separate from the LillyDirect self-pay vial program and savings cards. Eligibility typically requires documented low income and lack of adequate insurance coverage; applications require income verification and take time to process.

Sources

1. Eli Lilly, Zepbound pricing statement: Zepbound list price is $1,059.87 per month
2. FDA, Human Drug Compounding under Sections 503A and 503B of the FD&C Act: Legal framework allowing pharmacy compounding under 503A and 503B, including shortage-based exceptions
3. FDA Drug Shortages Database, Tirzepatide Injection: FDA resolved the tirzepatide injection shortage in December 2024
4. FDA, Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss: FDA has documented adverse events including dosing errors from compounded GLP-1 products
5. FDA, Compounded Semaglutide and Tirzepatide products safety communication: FDA warning about unverified salt forms in compounded tirzepatide not shown safe or effective
6. Social Security Act Section 1927(d)(2), 42 U.S.C. 1396r-8: Statutory exclusion for weight-loss agents affecting Medicare Part D coverage
7. Jastreboff et al., NEJM, SURMOUNT-1 Trial (NCT04184622): 20.9% average body weight loss at 15mg tirzepatide dose over 72 weeks versus 3.1% placebo
8. Frias et al., NEJM, SURPASS-2 Trial (NCT03987919): Tirzepatide reduced HbA1c by up to 2.30 percentage points, outperforming semaglutide 1mg
9. FDA, Zepbound Prescribing Information: Boxed warning for thyroid C-cell tumor risk and contraindication for MTC/MEN 2 history; pancreatitis and gallbladder disease risk